

Republic of the Philippines

Department of Education NEGROS ISLAND REGION

REGIONAL MEMORANDUM

No. _____, s. 2025

JUL 1 8 2025

GUIDANCE ON THE INCREASING CASES OF HAND, FOOT, AND MOUTH DISEASE (HFMD) IN DEPARTMENT OF EDUCATION NEGROS ISLAND REGION (DEPED NIR)

To: Schools Division Superintendents All Others Concerned

- 1. This Office through the Education Support Services- Health and Nutrition Unit (ESSD- HNU), disseminates the attached Department of Health Memorandum No. 2022-0572 or the "Guidelines on the Prevention, Detection, Isolation, Treatment, and Reintegration (PDITR) Strategy for HFMD."
- 2. All Schools Division Offices are requested to engage their School Health and Nutrition Units for them to remain vigilant, ensure timely reporting, and implement appropriate interventions to prevent possible outbreaks and protect the health and safety of learners and the broader community.
- 3. All Schools Division Offices, through the School Health and Nutrition Units, are reminded to update the DepEd NIR Online Hand Food and Mouth Disease Daily Situation Reporting Tool 2025, not later than 3:00 PM daily, to ensure timely submission of regional data and support accurate surveillance and reporting at all levels through https://forms.gle/sgHQQ2m5jNa4g6nK9.
- Immediate dissemination of and compliance with this Memorandum are desired.

RAMIR B. UYTICO EdD, CESO III
Regional Director

Encl.: DOH MEMO No. 0572, s2022
Reference: DOH MEMO No. 0572, s2022
To be indicated in the Perpetual Index under the following subjects:
DATA
HEALTH EDUCATION
PROCEDURE

SCHOOLS
MJM/ESSD/DEPEDNIR/Guidance on the Increasing Cases of Hand, Foot, and Mouth Disease (HFMD) in Department of Education Negros Island Region (DepEd NIR)/July 17, 2025







Address: Batinguel, Dumaguete City, 6200

Telephone Nos:

Email Address: nir@deped.gov.ph
Website: https://tinyurl.com/nir-gov-ph



Republic of the Philippines Department of Health OFFICE OF THE SECRETARY

November 28, 2022

DEPARTMENT MEMORANDUM

No. 2022 - 0572

FOR:

ALL UNDERSECRETARIES OF THE FIELD IMPLEMENTATION AND COORDINATION TEAMS, ALL DIRECTORS OF CENTERS FOR HEALTH DEVELOPMENT AND MINISTER OF HEALTH-BANGSAMORO AUTONOMOUS REGION IN MUSLIM MINDANAO, MEDICAL CENTER CHIEFS/HEADS OF DOH HOSPITALS,

AND OTHERS CONCERNED

SUBJECT:

Guidelines on the Prevention, Detection, Isolation, Treatment and Reintegration (PDITR) Strategy for Hand, Foot and Mouth

Disease (HFMD)

I. BACKGROUND

Hand, foot, and mouth disease (HFMD) is a highly contagious viral disease affecting various life stages but occurs most often in childhood. Most HFMD cases are mild, self-limiting, and non-fatal if caused by the enterovirus Coxsackievirus A16 (CA16) but may progress to meningitis, encephalitis, and polio-like paralysis if left unmanaged, sometimes resulting in death, if caused by Enterovirus 71 (EV71). The latter led HFMD to be included as one of the priority diseases/ syndromes/ conditions targeted for surveillance under Republic Act No. 11332, or the "Mandatory Reporting of Notifiable Diseases and Health Events of Public Health Concern Act" with a category of *immediately notifiable* or Category I.

In 2022, reported HFMD clusters peaked in October with a total of 38 health events. As of November 27, 2022, 3,365 HFMD cases have been reported but there are no reported fatalities in the Philippines. This Department Memorandum is hereby issued to provide additional guidance on the management of HFMD in facility, community, household, and individual-based settings in addition to the guidelines available in the Omnibus Health Guidelines per Lifestage as disseminated through Department of Health (DOH) Department Circular No. 2022-0344, DOH Department Memorandum (DM) No. 2020-0097: "Guidelines on the Implementation of Hand, Foot and Mouth Disease Surveillance, Clinical Management and Preventive Measures", and its reiteration in DM No. 2022-0034.

Currently, the Prevention, Detection, Isolation, Treatment, and Reintegration (PDITR) Strategy is being used to address HFMD and shall be the guiding principle in this issuance.

II. GENERAL GUIDELINES

A. Prevention

- Perform mandatory hand washing with soap and water, and hand hygiene using alcohol-based sanitizer, in all opportunities and occasions, especially in the hospital and household settings;
- 2. Strengthen infection prevention and control measures in all settings;
- 3. Avoid sharing of personal items such as spoons, cups, and utensils;
- 4. Use appropriate personal protective equipment (i.e. properly fitted face mask, gloves, and gown) when caring for a patient with HFMD; and
- Observe Minimum Public Health Standards (MPHS), especially when sneezing and coughing, as well as physical distancing.

B. Detection

- Assess the presence of common clinical manifestations for HFMD such as fever, mouth sores, and papulovesicular skin rash, which is usually seen in the palms of the hands and soles of the feet but may also occur as maculopapular rashes without vesicles and may also involve the buttocks, arms, and legs;
- Conduct history taking and complete physical examination, with particular attention on BP and HR measurement and neurologic examination to detect or elicit any warning sign of central and autonomic nervous system and cardiorespiratory system involvement (Annex A), which may warrant referral to a higher level of care;
- 3. Guidelines for public health surveillance are as follows:
 - All primary care providers, clinicians and public health authorities shall report any suspect, probable, and confirmed case within 24 hours to the DOH through the Local Epidemiology and Surveillance Units (ESU)
 - ii. Classify cases of HFMD following these prescribed definitions:
 - Suspect case Any individual, regardless of age, who developed acute febrile illness with papulovesicular or maculopapular rash on palms and soles, with or without vesicular lesion/ulcers in the mouth.
 - Probable case A suspected case that has not yet been confirmed by a laboratory test, but is geographically and temporally related to a laboratory-confirmed case.
 - Confirmed case A suspected/ probable case with positive laboratory result for human Enteroviruses that cause HFMD.
 - iii. Local ESUs shall report clusters of all Suspect, Probable, and Confirmed cases of HFMD immediately to the Event-based Surveillance and Response Unit of the Epidemiology Bureau
 - iv. Specimen samples for laboratory confirmation shall be collected from reported clusters of HFMD cases

- 4. Laboratory confirmation of HFMD cases shall be done through Reverse Transcription Polymerase Chain Reaction (RT-PCR) of throat swab, vesicles, or stool. However, clinical diagnosis is often sufficient and the absence of a confirmatory laboratory test should not hinder the initiation of case management.
- A completely filled out Case Report Form (Annex C) along with the specimen for laboratory confirmation shall be submitted to the Research Institute for Tropical Medicine (RITM)

C. Isolation

- Isolate patients with HFMD following standard precautions with droplet and contact infection control procedures. HFMD is mainly transmitted through person-to-person contact, including contact with infected nose and throat secretions or respiratory droplets, infected fluid from blisters or scabs, and infected fecal material; and
- Advise parents/guardians to ensure that children with suspect, probable, or confirmed HFMD should remain at home, avoid attending school, day-care facilities, or other face-to-face activities until the patient is already afebrile and all of his/her vesicles have dried up, and adhere to the advice of the Health Care Provider.

D. Treatment

 Classify the patient's disease stage or severity. Patients with Uncomplicated HFMD may be managed in an out-patient setting, while more severe cases should be given emergent management and referred for admission and inpatient care in a higher level facility with specialists. The classification for disease severity may be found in Annex A.

For Uncomplicated HFMD:

- i. Provide supportive treatment and prevent dehydration by ensuring appropriate fluid intake; and
- ii. Provide over-the-counter medications such as Paracetamol for fever and painful sores; and
- iii. Advise the patient and the parent/guardian to seek medical consultation immediately if symptoms persist beyond 10 days, if the condition becomes severe or is accompanied by nervous system and cardiorespiratory signs and symptoms as shown in Annex A.
- For HFMD with CNS Involvement, Autonomic Nervous System Dysregulation, or Cardiopulmonary Failure: provide basic emergency support and facilitate immediate referral and transfer to a hospital.

E. Reintegration

- Individuals with uncomplicated HFMD usually recover in 7 to 10 days and can resume regular activities upon recovery. Advise them to continue practicing the Minimum Public Health Standards (e.g., mask-wearing, respiratory hygiene/ cough etiquette, physical distancing, and hand washing/ hand sanitation); and
- Advise parents/guardians to prepare the child to return to school, day-care facilities, and attend other face-to-face activities depending on the assessment and advice of the attending physician.

For dissemination and compliance.

By Authority of the Secretary of Health:

BEVERLY LORR INE C. HO, MD, MPH OIC-Undersecretary of Health Public Health Services Team

ANNEX A. WHO Warning Signs for CNS Involvement in HFMD

Warning signs of CNS involvement includes one or more of the following:				
Fever ≥ 39°C or for ≥ 48 hours	Limb weakness			
Vomiting	Truncal ataxia			
Lethargy	"Wandering eyes"			
Agitation/irritability	Dyspnea/tachypnea			
Myoclonic jerks	Mottled skin			

ANNEX B. WHO Classification for Disease Severity in HFMD

Classification	Criteria		
Uncomplicated HFMD	Patients with no warning signs AND any of the following: Skin rash Oral Ulcers		
HFMD with CNS Involvement	Patients with HFMD AND any of the following: Meningism Myoclonic jerks Ataxia, tremors Lethargy Limb weakness		
HFMD with Autonomic Nervous System (ANS) Dysregulation	Patients with CNS involvement AND any of the following: Resting Heart Rate at 150-170 bpm Hypertension Profuse Sweating Respiratory Abnormalities (Tachypnea, Labored breathing)		
HFMD with Cardiopulmonary Failure	Patients with ANS Dysregulation AND any of the following: Hypotension/ Shock Pulmonary edema/ hemorrhage Heart Failure		

ANNEX C. PIDSR Case Report Form for Hand, Foot and Mouth Disease and Severe Enteroviral Disease

Name of DRU						
Address	Type C6	Type: DRHU DCHO DGov't Hospital DPrivate Hospital DClin DGov't Laboratory DPrivate Laboratory DArport/Seapo				
PATIENT INFORM	ATION					
atent Number		Patient's Fest N	lame	Middle Name	Las	! Name
omplete Address					Date of Bath	Age Sex
					minibally	
istrict			ILIZ:		_/_/_	D Days D Male D Months D Fema D Years
atient admitted?	YON	Date Admitte		<u> </u>	Date Onset	1 m m 1
ate of 100	T M T M N	Seen/Consultance of investigati			of filness Contact Nos	
westigation:						
CLINICAL INFOR	MATION					
ever: D	Y DN	Other si	gns/symptoms (please tick)	Are there any con	mplications?
Date onset/	/		riloss of appett		DY DN	
lash: DY DN			ly malaise		If YES, specify	(
Date onset	ngers		e throat isea & vomiting			
Oscies of feet DB			culty of breathin	iq.	Working/Final D	iagnosis
□Mouth ulcers		D Acu	te Flacoid Paral	yeis		agricus.
Painful?	Y DN		ningeal irritation		bath se	
Characteristic.		Others,	specify			
☐ macufopapular	☐ papulovesicula	te his end and thought to	specify		Ref med t	
O maculopapular	TORY	1 · · · · · · · · · · · · · · · · · · ·				
O maculopapular	TORY	1 · · · · · · · · · · · · · · · · · · ·		errec of HFMD o	or EV Disease?	0 Y 0 N
II. EXPOSURE HIST s there a history of tr	TORY avel within 12 wee	ks to an area w		errac of HFMD o	or EV Disease?	D Y D N
El maculopapular I. EXPOSURE HIST s there a history of to we there other known	TORY avel within 12 wee in cases in the com	ks to an area w		errac of HFMD o	or EV Disease?	
El maculopapular L EXPOSURE HIST s there a history of to we there other known	TORY avel within 12 wee in cases in the com	ks to an area w	ith ongoing epid	erric of HFMD o		
I maculopapular E EXPOSURE HIS there a history of truce there other known where did exposure p	TORY avel within 12 wee in cases in the com	ks to an area w munity?	ith ongoing epid	□Scho		DYDN
☐ maculopapular II. EXPOSURE HIS' Is there a history of tr. Are there other known Where did exposure p □Day care	avel within 12 wee in cases in the com probably occur?	ks to an area w munity?	ith ongoing epid	□Scho	i Health a d cast assa	DYDN
☐ maculopapular II. EXPOSURE HIST IS there a history of the IV. There other known IV. There did exposure is IDay care IDHome IV. LABORATORY 1	rORY avel within 12 wee in cases in the comprobably occur?	ks to an area w munity? DCommun DHealthCa	ith ongoing epid by re Facilities	El Scho El Other	of s. speaty	D Y D N
☐ maculopapular I. EXPOSURE HIST I. there a history of true there other know there did exposure p ☐Day care ☐Home	avel within 12 wee in cases in the com probably occur?	ks to an area w munity?	ith ongoing epid	□Scho □Other	of s. speaty	D Y D N
☐ maculopapular I. EXPOSURE HIST Is there a history of the re there other known Where did exposure p ☐Day care ☐Home V. LABORATORY 1	avel within 12 ween cases in the comprobably occur?	ks to an area w munity? DCommun DHealthCa	th ongoing epid	DScho DOther	ol s. specify Specify	D Y D N
☐ maculopapular I. EXPOSURE HIST I. there a history of true there other knows Where did exposure p ☐Day care ☐Home I. LABORATORY 1 Specimen	avel within 12 ween cases in the comprobably occur?	ks to an area w munity? DCommun DHealthCa	th ongoing epid	DScho DOther	ol s. specify Specify	D Y D N
☐ maculopapular I. EXPOSURE HIST I. The there is there a history of the there other known where did exposure policy care in the there is the the there is the the there is	avel within 12 ween cases in the comprobably occur?	ks to an area w munity? DCommun DHealthCa	th ongoing epid	DScho DOther	ol s. specify Specify	D Y D N
☐ maculopapular I. EXPOSURE HIST Is there a history of to the there other know Where did exposure of ☐Day care ☐Home V. LABORATORY I Specimen ☐Throat swab	avel within 12 ween cases in the comprobably occur?	ks to an area w munity? DCommun DHealthCa	th ongoing epid	DScho DOther	ol s. specify Specify	D Y D N
D maculopapular I. EXPOSURE HIST I. there a history of true there other know where did exposure published to the third theme. I. LABORATORY I. Specimen Throat swab I. Vesicle swab Rectal swab	rory avel within 12 wee in cases in the comprobably occur? rests if YES, Date Coffected	ks to an area w munity? DCommun DHealthCa	th ongoing epid	DScho DOther	Specify organism	D Y D N
D maculopapular I. EXPOSURE HIST II. there a history of true there other know where did exposure published theme II. LABORATORY 1 Specimen IThroat swab IVesicle swab I Stool	rory avel within 12 wee in cases in the comprobably occur? IESTS If YES, Date Collected	ks to an area w munity? DCommun DHealthCa	ty Date received at RITM	Result: Floative: Niega-	Specify organism	Date of resul
☐ maculopapular I. EXPOSURE HIST I. there a history of true there other know there did exposure p ☐Day care ☐Home I. LABORATORY I Specimen [Throat swab [Vesicle swab [Rectal swab] Stool CLASSIFICATION	avel within 12 wee in cases in the comprobably occur? If YES, Date Collected	ks to an area wemunity? Dicommun DiHealthCa	ty Date received at RITM	Result: Floative: Nega- Sive Not Done VI. OUTCOME	Specify organism	Date of results